Gain Therapeutics, Inc.
$1.65+3.77%(+$0.06)
TickerSpark Score
51/100
60
Valuation
20
Profitability
60
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GANX research report →
52-Week Range8% of range
Low $1.41
Current $1.65
High $4.34
Companywww.gaintherapeutics.com
Gain Therapeutics, Inc. , a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders.
- CEO
- Gene Mack
- IPO
- 2021
- Employees
- 23
- HQ
- Bethesda, MD, US
Price Chart
-13.61% · this period
Valuation
- Market Cap
- $70.38M
- P/E
- -3.28
- P/S
- 0.00
- P/B
- 4.97
- EV/EBITDA
- -2.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -201.43%
- ROIC
- -131.58%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-20,161,099 · 1.23%
- EPS
- $-0.61 · 31.46%
- Op Income
- $-18,710,702
- FCF YoY
- 2.28%
Performance & Tape
- 52W High
- $4.34
- 52W Low
- $1.41
- 50D MA
- $1.98
- 200D MA
- $2.19
- Beta
- 0.15
- Avg Volume
- 690.68K
Get TickerSpark's AI analysis on GANX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 24, 26 | Mack Gene | other | 200,000 |
| Mar 24, 26 | Fuggetta Gianluca | other | 50,000 |
| Jun 24, 25 | Islam Khalid | other | 15,000 |
| Jun 24, 25 | Nicaise Claude | other | 15,000 |
| Jun 24, 25 | Riley Jeffrey Scott | other | 15,000 |
| Jun 24, 25 | RICHMAN ERIC I | other | 15,000 |
| Jun 24, 25 | HASLER HANS PETER | other | 15,000 |
| Jun 24, 25 | GOLDSTEIN DOV A MD | other | 15,000 |
| Jun 24, 25 | Melincoff Gwen A | other | 15,000 |
| Mar 20, 25 | Fuggetta Gianluca | other | 50,000 |
Our GANX Coverage
We haven't published any research on GANX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GANX Report →